ABSTRACT
Abstract Bone morphogenetic protein type 2 (BMP-2) and retinoic acid (RA) are osteoinductive factors that stimulate endogenous mechanisms of bone repair which can be applied on management of osseous defects in oral and maxillofacial fields. Objective Considering the different results of RA on osteogenesis and its possible use to substitute/potency BMP-2 effects, this study evaluated the outcomes of BMP-2, RA, and BMP-2+RA treatments on in vitro osteogenic differentiation of human adipose-derived stem cells (ASCs) and the signaling pathway(s) involved. Material and Methods ASCs were treated every other day with basic osteogenic medium (OM) alone or supplemented with BMP-2, RA, or BMP-2+RA. Alkaline phosphatase (ALP) activity was determined using the r-nitrophenol method. Extracellular matrix mineralization was evaluated using von Kossa staining and calcium quantification. Expression of osteonectin and osteocalcin mRNA were determined using qPCR. Smad1, Smad4, phosphorylated Smad1/5/8, BMP-4, and BMP-7 proteins expressions were analyzed using western blotting. Signaling pathway was evaluated using the IPA® software. Results RA promoted the highest ALP activity at days 7, 14, 21, and 28, in comparison to BMP-2 and BMP-2+RA. BMP-2+RA best stimulated phosphorylated Smad1/5/8 protein expression at day 7 and Smad4 expression at days 7, 14, 21, and 28. Osteocalcin and osteonectin mRNA expressions were best stimulated by BMP-2+RA at day 7. Matrix mineralization was most improved by BMP-2+RA at days 12 and 32. Additionally, BMP-2+RA promoted the highest BMP signaling pathway activation at days 7 and 14, and demonstrated more activation of differentiation of bone-forming cells than OM alone. Conclusions In summary, RA increased the effect of BMP-2 on osteogenic differentiation of human ASCs.
Subject(s)
Humans , Osteogenesis/drug effects , Tretinoin/pharmacology , Cell Differentiation/drug effects , Bone Morphogenetic Protein 2/drug effects , Mesenchymal Stem Cells/drug effects , Osteoblasts/drug effects , Osteogenesis/physiology , Reference Values , Time Factors , Osteocalcin/analysis , Osteocalcin/drug effects , Osteonectin/analysis , Osteonectin/drug effects , Cell Differentiation/physiology , Cells, Cultured , Blotting, Western , Reproducibility of Results , Analysis of Variance , Alkaline Phosphatase/analysis , Alkaline Phosphatase/adverse effects , Bone Morphogenetic Protein 2/metabolism , Mesenchymal Stem Cells/metabolismABSTRACT
This aim of this study was to assess the molecular mechanism of osteoporosis in schizophrenia patients with risperidone use. Here, we investigated the effects of risperidone on cellular proliferation and apoptosis of a preosteoblast cell line, MC3T3-E1. Cell viability and apoptotic rate of MC3T3-E1 were detected by cell counting kit-8 and flow cytometry at a serial dose of risperidone and at different time points, respectively. Bone transformation relevant gene serum osteocalcin (BGP), collagen 1, tumor necrosis factor-α (TNF-α), osteoprotegerin (OPG), and receptor activator of nuclear factor-κB ligand (RANKL) mRNA levels were determined by real-time PCR (qPCR). Their protein expression patterns were evaluated using western blot. The results revealed that risperidone dramatically inhibited MC3T3-E1 cell proliferation in a dose-dependent manner. It also significantly induced MC3T3-E1 cell apoptosis. TNF-α gene and protein levels were greatly enhanced after risperidone treatment. In contrast, BGP, collagen 1, OPG, and RANKL gene and protein levels were markedly downregulated. Our study indicated that risperidone suppressed MC3T3-E1 cell proliferation and induced apoptosis. It also regulated BGP gene and protein expression.
Subject(s)
Animals , Osteoblasts/drug effects , Apoptosis/drug effects , Risperidone/pharmacology , Cell Proliferation/drug effects , Osteocalcin/drug effects , Cell Line , Collagen/drug effects , Tumor Necrosis Factor-alpha/drug effects , Receptor Activator of Nuclear Factor-kappa B/drug effects , Osteoprotegerin/drug effects , Flow CytometryABSTRACT
ABSTRACT Objective: This study evaluated the effects of combination therapy of curcumin and alendronate on BMD and bone turnover markers in postmenopausal women with osteoporosis. Subjects and methods: In a randomized, double-blind trial study, 60 postmenopausal women were divided into three groups: control, alendronate, and alendronate + curcumin. Each group included 20 patients. Total body, total hip, lumbar spine and femoral neck BMDs were measured by dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of therapy. Bone turnover markers such as bone-specific alkaline phosphatase (BALP), osteocalcin and C-terminal cross-linking telopeptide of type I collagen (CTx) were measured at the outset and 6 months later. Results: Patients in the control group suffered a significant decrease in BMD and increased bone turnover markers at the end of study. The group treated with only alendronate showed significantly decreased levels of BALP and CTx and increased levels of osteocalcin compared to the control group. The alendronate group also showed significant increases in the total body, total hip, lumbar spine and femoral neck BMDs at the end of study compared to the control group. In the curcumin + alendronate group, BALP and CTx levels decreased and osteocalcin levels increased significantly at the end of study compared to the control and alendronate groups. BMD indexes also increased in four areas significantly at the end of study compared to the control and alendronate groups. Conclusion: The combination of curcumin and alendronate has beneficial effects on BMD and bone turnover markers among postmenopausal women with osteoporosis. Arch Endocrinol Metab. 2018;62(4):438-45
Subject(s)
Humans , Female , Middle Aged , Aged , Bone Density/drug effects , Osteoporosis, Postmenopausal/metabolism , Alendronate/pharmacology , Curcumin/pharmacology , Bone Density Conservation Agents/pharmacology , Peptide Fragments/drug effects , Peptide Fragments/urine , Osteocalcin/analysis , Osteocalcin/drug effects , Double-Blind Method , Bone Remodeling/drug effects , Collagen Type II/drug effects , Collagen Type II/urine , Drug Therapy, Combination/methods , Alkaline Phosphatase/analysis , Alkaline Phosphatase/drug effectsABSTRACT
Abstract Raloxifene is an antiresorptive drug, selective estrogen receptor modulator (SERM) used in the treatment of osteoporosis. Objective To evaluate proteins related to bone repair at the peri-implant bone in a rat model of osteoporosis treated with raloxifene. Material and Methods 72 rats were divided into three groups: SHAM (healthy animals), OVX (ovariectomized animals), and RLX (ovariectomized animals treated with raloxifene). Raloxifene was administered by gavage (1 mg/kg/day). Tibial implantation was performed 30 days after ovariectomy, and animals were euthanized at 14, 42, and 60 days postoperatively. Samples were collected and analyzed by immunohistochemical reactions, molecular analysis, and microtomographic parameters. Results RLX showed intense staining of all investigated proteins at both time points except for RUNX2. These results were similar to SHAM and opposite to OVX, showing mild staining. The PCR gene expression of OC and ALP values for RLX (P<0.05) followed by SHAM and OVX groups. For BSP data, the highest expression was observed in the RLX groups and the lowest expression was observed in the OVX groups (P<0.05). For RUNX2 data, RLX and SHAM groups showed greater values compared to OVX (P<0.05). At 60 days postoperatively, microtomography parameters, related to closed porosity, showed higher values for (Po.N), (Po.V), and (Po) in RLX and SHAM groups, whereas OVX groups showed lower results (P<0.05); (BV) values (P=0.009); regarding total porosity (Po.tot), RLX group had statistically significant lower values than OVX and SHAM groups (P=0.009). Regarding the open porosity (Po.V and Po), the SHAM group presented the highest values, followed by OVX and RLX groups (P<0.05). The Structural Model Index (SMI), RLX group showed a value closer to zero than SHAM group (P<0.05). Conclusions Raloxifene had a positive effect on the expression of osteoblastogenesis/mineralization-related proteins and on micro-CT parameters related to peri-implant bone healing.
Subject(s)
Animals , Female , Osteoblasts/drug effects , Osteogenesis/drug effects , Osteoporosis/drug therapy , Proteins/analysis , Proteins/drug effects , Raloxifene Hydrochloride/pharmacology , Selective Estrogen Receptor Modulators/pharmacology , Osteoporosis/pathology , Reference Values , Time Factors , Immunohistochemistry , Ovariectomy , Gene Expression , Osteocalcin/analysis , Osteocalcin/drug effects , Polymerase Chain Reaction , Reproducibility of Results , Treatment Outcome , Rats, Wistar , Disease Models, Animal , Wnt Proteins/analysis , Wnt Proteins/drug effects , beta Catenin/analysis , beta Catenin/drug effects , Core Binding Factor Alpha 1 Subunit/analysis , Core Binding Factor Alpha 1 Subunit/drug effects , Osteopontin/analysis , Osteopontin/drug effects , X-Ray MicrotomographyABSTRACT
Abstract Sodium alendronate is a bisphosphonate drug that exerts antiresorptive action and is used to treat osteoporosis. Objective The aim of this study was to evaluate the bone repair process at the bone/implant interface of osteoporotic rats treated with sodium alendronate through the analysis of microtomography, real time polymerase chain reactions and immunohistochemistry (RUNX2 protein, bone sialoprotein (BSP), alkaline phosphatase, osteopontin and osteocalcin). Material and Methods A total of 42 rats were used and divided in to the following experimental groups: CTL: control group (rats submitted to fictitious surgery and fed with a balanced diet), OST: osteoporosis group (rats submitted to a bilateral ovariectomy and fed with a low calcium diet) and ALE: alendronate group (rats submitted to a bilateral ovariectomy, fed with a low calcium diet and treated with sodium alendronate). A surface treated implant was installed in both tibial metaphyses of each rat. Euthanasia of the animals was conducted at 14 (immunhostochemistry) and 42 days (immunohistochemistry, micro CT and PCR). Data were subjected to statistical analysis with a 5% significance level. Results Bone volume (BV) and total pore volume were higher for ALE group (P<0.05). Molecular data for RUNX2 and BSP proteins were significantly expressed in the ALE group (P<0.05), in comparison with the other groups. ALP expression was higher in the CTL group (P<0.05). The immunostaining for RUNX2 and osteopontin was positive in the osteoblastic lineage cells of neoformed bone for the CTL and ALE groups in both periods (14 and 42 days). Alkaline phosphatase presented a lower staining area in the OST group compared to the CTL in both periods and the ALE at 42 days. Conclusion There was a decrease of osteocalcin precipitation at 42 days for the ALE and OST groups. Therefore, treatment with short-term sodium alendronate improved bone repair around the implants installed in the tibia of osteoporotic rats.
Subject(s)
Animals , Female , Osteoporosis/drug therapy , Dental Implants , Osseointegration/drug effects , Alendronate/pharmacology , Bone Density Conservation Agents/pharmacology , Osteoblasts/drug effects , Osteoporosis/physiopathology , Tibia/surgery , Time Factors , Immunohistochemistry , Ovariectomy , Bone Density/drug effects , Osteocalcin/analysis , Osteocalcin/drug effects , Cell Differentiation/drug effects , Reproducibility of Results , Rats, Wistar , Implants, Experimental , Dental Implantation, Endosseous , Alkaline Phosphatase/analysis , Alkaline Phosphatase/drug effects , Core Binding Factor Alpha 1 Subunit/analysis , Core Binding Factor Alpha 1 Subunit/drug effects , Osteopontin/analysis , Osteopontin/drug effects , X-Ray Microtomography , Real-Time Polymerase Chain ReactionABSTRACT
BACKGROUND: Tridaxprocumbens flavonoids (TPFs) are well known for their medicinal properties among local natives. Besides traditionally used for dropsy, anemia, arthritis, gout, asthma, ulcer, piles, and urinary problems, it is also used in treating gastric problems, body pain, and rheumatic pains of joints. TPFs have been reported to increase osteogenic functioning in mesenchymal stem cells. Our previous study showed that TPFs were significantly suppressed the RANKL-induced differentiation of osteoclasts and bone resorption. However, the effects of TPFs to promote osteoblasts differentiation and bone formation remain unclear. TPFs were isolated from Tridax procumbens and investigated for their effects on osteoblasts differentiation and bone formation by using primary mouse calvarial osteoblasts. RESULTS: TPFs promoted osteoblast differentiation in a dose-dependent manner demonstrated by up-regulation of alkaline phosphatase and osteocalcin. TPFs also upregulated osteoblast differentiation related genes, including osteocalcin, osterix, and Runx2 in primary osteoblasts. TPFs treated primary osteoblast cells showed significant upregulation of bone morphogenetic proteins (BMPs) including Bmp-2, Bmp-4, and Bmp-7. Addition of noggin, a BMP specific-antagonist, inhibited TPFs induced upregulation of the osteocalcin, osterix, and Runx2. CONCLUSION: Our findings point towards the induction of osteoblast differentiation by TPFs and suggested that TPFs could be a potential anabolic agent to treat patients with bone loss-associated diseases such as osteoporosis.
Subject(s)
Animals , Mice , Osteoblasts/drug effects , Osteogenesis/drug effects , Flavonoids/pharmacology , Cell Differentiation/drug effects , Asteraceae/chemistry , Osteoblasts/cytology , Osteoblasts/metabolism , Skull/cytology , Skull/drug effects , Transcription Factors/genetics , Flavonoids/analysis , Calcification, Physiologic/drug effects , Osteocalcin/drug effects , Osteocalcin/genetics , Up-Regulation/genetics , Bone Morphogenetic Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Alkaline Phosphatase/drug effects , Alkaline Phosphatase/metabolism , Core Binding Factor Alpha 1 Subunit/genetics , Core Binding Factor Alpha 1 Subunit/metabolism , Primary Cell Culture , Sp7 Transcription Factor , Medicine, Traditional , Mice, Inbred C57BLABSTRACT
Osteoporosis is a chronic disease characterized by a decrease in bone mineral density [BMD] and corruption of the microarchitectural structure of bone tissue. It was investigated whether methylprednisolone had a favorable effect on osteoporotic bone tissue in Oophorectomy induced osteoporotic rats whose endogenous adrenaline levels are suppressed with metyrosine. Bone Mineral Density, number of osteoblast-osteoclast, bone osteocalcin levels and alkaline phosphatase [ALP] measurements were performed. Obtained results were compared with that of alendronate. Oophorectomy induced osteoporosis was exacerbated by methylprednisolone. Alentronate prevented ovariectomised induced osteoporosis, but it couldn't prevent methylprednisolone +ovariectomised induced osteoporosis in rats. Combined treatment with methylprednisolon and metyrosine was the best treatment for preventing osteoporosis but metyrosine alone couldn't prevent osteoporosis in ovariectomised rats
Subject(s)
Female , Animals, Laboratory , Methyltyrosines , Rats , Osteoclasts/drug effects , Prednisolone , Prednisolone/adverse effects , Drug Combinations , Ovariectomy/adverse effects , Osteoblasts/drug effects , Bone Density/drug effects , Methylprednisolone/adverse effects , Methylprednisolone , Osteocalcin/drug effects , Alkaline Phosphatase , Alendronate , Treatment OutcomeABSTRACT
The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.
Subject(s)
Alkaline Phosphatase/drug effects , Biomarkers/analysis , Bone Density/drug effects , Bone Density Conservation Agents/administration & dosage , Bone Resorption/drug therapy , Bone and Bones/drug effects , Drug Monitoring , Etidronic Acid/administration & dosage , Female , Humans , Middle Aged , Osteocalcin/drug effects , Osteoporosis, Postmenopausal/drug therapy , Peptide Fragments/drug effects , Procollagen/drug effects , Time Factors , Treatment Outcome , Vitamin K DeficiencyABSTRACT
Teeth have been recognized as providing a useful long-term record of lead (Pb2+) uptake. However, information regarding the effects of lead on dental pulp tissue cells that foster dentinogenesis is scarce. This study investigated the effects of lead on dental pulp tissue using human dental pulp fibroblasts in vitro. Dental pulp cells from the teeth of young patients (aged 17-24 years) were cultured and subsequently treated with lead glutamate. It was shown that, in serum-free conditions, all the tested concentrations of lead (4.5 x 10(-5) M, 4.5 x 10(-6) M, and 4.5 x 10(-7) M) significantly increased pulpal cell proliferation. In the presence of 2% fetal bovine serum, increasing cell proliferation was observed only after exposure to a lead concentration of 4.5 x 10(-5) M. However, protein, procollagen type I, and osteocalcin productions were significantly decreased. The alteration of cell population and protein production of affected human dental pulp shown in this study are toxic effects of the lead.
Subject(s)
Adolescent , Adult , Analysis of Variance , Cell Division/drug effects , Cells, Cultured , Collagen Type I/drug effects , Dental Pulp/cytology , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Humans , Lead/toxicity , Lead Poisoning/diagnosis , Osteocalcin/drug effects , Protein Biosynthesis , Proteins/drug effectsSubject(s)
Humans , Infant , Child, Preschool , Child , Adolescent , Adult , Adrenal Cortex Hormones/adverse effects , Glucocorticoids/adverse effects , Growth Disorders/etiology , Growth/drug effects , Administration, Inhalation , Asthma/complications , Asthma/drug therapy , Bone and Bones/drug effects , Bone Density , Bone Demineralization, Pathologic/etiology , Osteocalcin/drug effects , Practice Guidelines as Topic , Self-Evaluation ProgramsABSTRACT
Se reportan cuatro casos de pacientes del sexo femenino con pénfigo tratado con deflazacort (1.25 mg/kg/día), glucocorticoide semejante a la prednisona, pero con menos efectos en el metabolismo del calcio y carbohidratos. Se realizaron evaluaciones de variables de eficacia, como días para el control (ausencia de nuevas ampollas), y de seguridad, como glucemia y densitometría ósea. En un promedio de 28.7 días se logró el control del pénfigo con una dosis total promedio de deflazocort de 2,3175 mg. El deflazacort resultó eficaz en el control del pénfigo, con mínimos efectos secundarios. Son deseables ensayos clínicos controlados comparativos con prednisona y de mayor seguimiento